Not Yet RecruitingNot Applicable

Evaluation of Resveratrol and Its Loaded Nanoparticles on Acanthamoeba

50 participantsStarted 2025-10-15

Plain-language summary

Acanthamoeba is a free-living amoeba responsible for severe human infections. There are at least twenty-two different genotypes of Acanthamoeba (T1-T22). T4 is the most common virulent genotype, mainly Acanthamoeba castellani and Acanthamoeba polyphaga. Proper treatment still represents a challenge for healthcare professionals.So, we need novel therapeutic strategies, including newer drugs and/or drug delivery systems that can overcome the developing drug resistance as well as have minimal toxicity to human cells. There is a new approach in the treatment of parasitic disease by using nanotechnology and natural compounds as plant extracts. The current study aims to evaluate the therapeutic potential of resveratrol, both in its free form and when loaded on nanoparticles, against clinically isolated Acanthamoeba strains obtained from patients with persistent AK or corneal ulcers.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients presented with keratitis to the outpatient clinic.
. Patients presented with corneal ulcers to the outpatient clinic.

Exclusion criteria

. Patients presented with corneal ulcers caused by pathogens rather than Acanthamoeba (bacterial, viral or fungal).
. Patients presented with other eye conditions that act as confounding variable as corneal perforation, severe dry eye, glaucoma, scleritis and active uveitis.
. Patients with history of previous ocular surgery or corneal transplant.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Invitro evaluation of amoebicidal efficacy of resveratrol and resveratrol loaded nanoparticles against the isolated Acanthamoeba pathogenic strains from corneal ulcers patients in comparison to the reference drug through experimental study.

Timeframe: 2025-2028

Invivo evaluation of amoebicidal efficacy of resveratrol and resveratrol loaded nanoparticles against the isolated Acanthamoeba pathogenic strains from corneal ulcers patients in comparison to the reference drug through experimental study.

Timeframe: 2025-2028

Trial details

NCT IDNCT07148752

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-10-30

View on ClinicalTrials.gov More Corneal Ulcer Caused by Acanthamoeba trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients presented with keratitis to the outpatient clinic.
. Patients presented with corneal ulcers to the outpatient clinic.

Exclusion criteria

. Patients presented with corneal ulcers caused by pathogens rather than Acanthamoeba (bacterial, viral or fungal).
. Patients presented with other eye conditions that act as confounding variable as corneal perforation, severe dry eye, glaucoma, scleritis and active uveitis.
. Patients with history of previous ocular surgery or corneal transplant.

What they're measuring

Timeframe: 2025-2028